Clinical trials with mAbs to PD-1 and PD-L1 have shown impressive response rates in patients, particularly for melanoma, NSCLC, RCC, and bladder cancer (Ohaegbulam et al., 2015). This evidence concerns the gene CD274 and non-small cell lung carcinoma.